PDCD1 and neoplasm: Our preclinical studies in both anti-PD-1-sensitive and anti-PD-1-resistant mouse tumor models demonstrated that mAWT020 exhibited superior anti-tumor efficacy compared to either anti-PD-1 antibody or IL-2 alone, or their combination.